Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan in the Netherlands (2017-2024): a retrospective, multicentre cohort study.
Saved in:
| Title: | Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan in the Netherlands (2017-2024): a retrospective, multicentre cohort study. |
|---|---|
| Authors: | Peeters SLJ; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands.; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre Leiden, the Netherlands., Heersche N; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands.; Department of Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, the Netherlands., Böhm D; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands.; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre Leiden, the Netherlands., Böhringer S; Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, Netherlands., Guiljam R; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands., Hulshof EC; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands.; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre Leiden, the Netherlands., de Man FM; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands., de With M; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands.; Department of Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, the Netherlands., Joosse M; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands., Oomens G; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands., Wu QY; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre Leiden, the Netherlands., Osman A; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands., Bins S; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands., van Hellemond IEG; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands., Haberkorn BCM; Department of Medical Oncology, Maasstad Hospital, Rotterdam, the Netherlands., Verschoor AJ; Department of Medical Oncology, Reinier de Graaf Gasthuis, Delft, the Netherlands., Wumkes ML; Department of Medical Oncology, Jeroen Bosch Hospital, 's Hertogenbosch, the Netherlands., van Schaik RHN; Department of Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, the Netherlands., Thijs AM; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands., Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre Leiden, the Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands., Deenen MJ; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands.; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre Leiden, the Netherlands. |
| Source: | The Lancet regional health. Europe [Lancet Reg Health Eur] 2026 Feb 23; Vol. 64, pp. 101629. Date of Electronic Publication: 2026 Feb 23 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: [Oxford] Country of Publication: England NLM ID: 101777707 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-7762 (Electronic) Linking ISSN: 26667762 NLM ISO Abbreviation: Lancet Reg Health Eur Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
